NIKI Niki BioSolutions, Inc.
$1.89▲ +3.28%
Healthcare
Other
Volume 12.6K
Avg Volume (10D) 19.8K
Key Metrics & Fundamentals
Market Cap
$5.89M
P/E Ratio
–
Div Yield
0.00%
52W Range
1.81 - 17.20
% vs 50 MA
-63.15%
% vs 200 MA
-76.03%
RSI-14
20.6
MACD Histogram
-0.0400
Beta (1Y vs SPY)
1.42
Free Cash Flow
-$535,719
Gross Rev
$0
Gross Profit
$0
EBITDA
-$1.36M
COGS
–
Operating Exp
$825,131
Operating Income
-$825,131
EBIT
-$825,131
Pretax Income
-$310,540
Net Income
-$307,495
Price & Volume History
Loading chart…
Recent News
Niki BioSolutions Announces New York State Approval for Its APOE Genotyping Test Using Dried Blood Spots, Plasma, and Urine
GlobeNewswire · Oct 26, 2026 9:15 AM ET
Niki BioSolutions Signs Agreement to Supply APOE Genotyping to Charter Research
GlobeNewswire · Oct 23, 2026 8:00 AM ET
Niki BioSolutions’ Rett Syndrome Biomarker Program Featured in the International Rett Syndrome Foundation’s “Rett Research Tool Belt” Series
GlobeNewswire · Oct 16, 2026 8:00 AM ET
Niki BioSolutions Partners with Global Alzheimer’s Platform Foundation to Deliver Plasma-Based APOE Genotyping for Bio-Hermes-002
GlobeNewswire · Oct 14, 2026 8:00 AM ET
Niki BioSolutions Accelerates Its Alzheimer’s Disease Testing Pipeline Through Strategic Bioinformatics and Statistical Analysis Partnership with Fios Genomics
GlobeNewswire · Sep 14, 2026 8:30 AM ET
Niki BioSolutions to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
GlobeNewswire · Sep 8, 2026 8:00 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See NIKI's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.